In a study trial, pharmaceutical giant Eli Lilly's weight-loss drug Zepbound showed better results than another pharmaceutical company, Novo Nordisk's weight-loss drug Wegovy. The trial, called SURMOUNT-5, compared Zepbound to Wegovy, which is a mono GLP-1 receptor agonist in adults living with obesity without diabetes. The results showed Zepbound delivering a remarkable 47% greater relative weight loss compared to Wegovy, …
Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …
In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy. The details People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly- That translated into an average 50-pound loss for people who took Zepbound, while Wegovy users lost …
